New Jersey Wins $9.5 Million in Landmark Opioid Settlement with Publicis Health

The settlement emerged from <a href="https://www.nj.gov/oag/newsreleases24/2024-0201_Publicis-Complaint.pdf" rel="noopener ugc nofollow" target="_blank">allegations against Publicis</a> for engaging in practices deemed unconscionable by the New Jersey Consumer Fraud Act. Publicis’s acknowledgment of the harm caused by its actions paves the way for enhanced support for communities grappling with the opioid crisis, focusing on treatment, recovery, and the development of sustainable infrastructure to save lives. Central to the state’s complaint were accusations of Publicis’s involvement in marketing strategies that significantly contributed to the opioid crisis. The firm’s collaboration with Purdue Pharma and other manufacturers in promoting opioid sales through various unethical practices, including exploiting personal health conversations and manipulating electronic health records, has been particularly scrutinized. These strategies not only increased opioid sales but also played a significant role in fueling the crisis that has led to over 9,800 prescription opioid overdose deaths in New Jersey over the past decade. <a href="https://medium.com/@MorristownMinute/new-jersey-wins-9-5-million-in-landmark-opioid-settlement-with-publicis-health-51071de989f0">Read More</a>